Literature DB >> 11252148

Pharmacologic treatment of neuropathic pain.

M S Wallace1.   

Abstract

Neuropathic pain, or pain after nervous system injury, can be very refractory to pharmacologic interventions. Through a better understanding of the pathophysiology of neuropathic pain, it has been suggested that nonopioid agents, such as antidepressants and anticonvulsants, may be more efficacious in the treatment of neuropathic pain than common analgesics, such as opioids or nonsteroidal anti-inflammatory drugs. However, this has not been consistently demonstrated in clinical studies. Conversely, many confounding factors of neuropathic pain make it difficult to interpret clinical studies. Therefore, we must develop a better understanding of the preclinical models of neuropathic pain to better understand the application of new and old drugs to the human neuropathic pain state. This article provides an overview of the commonly used preclinical neuropathic pain models, followed by a summary of the efficacy of currently available agents in preclinical pain models and human correlates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11252148     DOI: 10.1007/s11916-001-0082-2

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  110 in total

1.  Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy.

Authors:  E Lang; H A Hord; D Denson
Journal:  Pain       Date:  1996-11       Impact factor: 6.961

Review 2.  Calcium channels in vertebrate cells.

Authors:  P Hess
Journal:  Annu Rev Neurosci       Date:  1990       Impact factor: 12.449

Review 3.  Glutamate receptors in the mammalian central nervous system.

Authors:  S Ozawa; H Kamiya; K Tsuzuki
Journal:  Prog Neurobiol       Date:  1998-04       Impact factor: 11.685

4.  Reflex sympathetic dystrophy treated with gabapentin.

Authors:  G A Mellick; L B Mellick
Journal:  Arch Phys Med Rehabil       Date:  1997-01       Impact factor: 3.966

5.  The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain.

Authors:  J C Hunter; K R Gogas; L R Hedley; L O Jacobson; L Kassotakis; J Thompson; D J Fontana
Journal:  Eur J Pharmacol       Date:  1997-04-18       Impact factor: 4.432

6.  Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC).

Authors:  K Gohil; J R Bell; J Ramachandran; G P Miljanich
Journal:  Brain Res       Date:  1994-08-08       Impact factor: 3.252

7.  Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study.

Authors:  B S Galer; J Harle; M C Rowbotham
Journal:  J Pain Symptom Manage       Date:  1996-09       Impact factor: 3.612

8.  Mexiletine for painful alcoholic neuropathy.

Authors:  K Nishiyama; M Sakuta
Journal:  Intern Med       Date:  1995-06       Impact factor: 1.271

9.  Peripheral analgesic effect of intra-articular clonidine.

Authors:  M Gentili; A Juhel; F Bonnet
Journal:  Pain       Date:  1996-03       Impact factor: 6.961

10.  Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE2 and in the chronic hyperalgesia in rats with streptozotocin-induced diabetes.

Authors:  Meire Nakamura-Craig; Rhonda Lesley Follenfant
Journal:  Pain       Date:  1995-10       Impact factor: 6.961

View more
  2 in total

1.  Midazolam administration reverses thermal hyperalgesia and prevents gamma-aminobutyric acid transporter loss in a rodent model of neuropathic pain.

Authors:  Andre Shih; Vjekoslav Miletic; Gordana Miletic; Lesley J Smith
Journal:  Anesth Analg       Date:  2008-04       Impact factor: 5.108

2.  Is there a reasonable excuse for not providing post-operative analgesia when using animal models of peripheral neuropathic pain for research purposes?

Authors:  Sara Hestehave; Gordon Munro; Rie Christensen; Tina Brønnum Pedersen; Lars Arvastson; Philip Hougaard; Klas S P Abelson
Journal:  PLoS One       Date:  2017-11-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.